Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 19 | 2023 | 3181 | 2.190 |
Why?
|
Kidney Neoplasms | 19 | 2023 | 4274 | 1.970 |
Why?
|
Sezary Syndrome | 2 | 2022 | 70 | 0.940 |
Why?
|
Mycosis Fungoides | 2 | 2022 | 155 | 0.880 |
Why?
|
Anilides | 3 | 2021 | 415 | 0.880 |
Why?
|
Urinary Bladder Neoplasms | 4 | 2024 | 2176 | 0.870 |
Why?
|
Immunotherapy | 10 | 2022 | 4752 | 0.730 |
Why?
|
Carcinoma, Transitional Cell | 3 | 2023 | 790 | 0.710 |
Why?
|
Mucositis | 1 | 2021 | 107 | 0.700 |
Why?
|
Cell Adhesion Molecules | 1 | 2024 | 1612 | 0.590 |
Why?
|
Sarcopenia | 4 | 2022 | 378 | 0.510 |
Why?
|
Pyridines | 3 | 2021 | 2888 | 0.480 |
Why?
|
Skin Neoplasms | 4 | 2022 | 5849 | 0.450 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 11868 | 0.420 |
Why?
|
Adiposity | 2 | 2020 | 1890 | 0.420 |
Why?
|
Interleukin-2 | 1 | 2019 | 1896 | 0.390 |
Why?
|
Neoplasms | 7 | 2022 | 22340 | 0.350 |
Why?
|
Interferon-gamma | 1 | 2019 | 3160 | 0.350 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2022 | 196 | 0.330 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 3078 | 0.330 |
Why?
|
Retrospective Studies | 26 | 2024 | 81514 | 0.300 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5696 | 0.290 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5753 | 0.280 |
Why?
|
Georgia | 2 | 2020 | 186 | 0.210 |
Why?
|
Hypoalbuminemia | 1 | 2022 | 90 | 0.190 |
Why?
|
Hypertension | 1 | 2021 | 8626 | 0.190 |
Why?
|
Immune System Diseases | 1 | 2023 | 251 | 0.180 |
Why?
|
Methemoglobinemia | 1 | 2021 | 48 | 0.180 |
Why?
|
Acetamides | 1 | 2022 | 260 | 0.180 |
Why?
|
Obesity | 2 | 2020 | 13076 | 0.170 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9249 | 0.170 |
Why?
|
Prognosis | 10 | 2022 | 29922 | 0.170 |
Why?
|
Liver Neoplasms | 3 | 2021 | 4353 | 0.170 |
Why?
|
Male | 25 | 2024 | 363698 | 0.170 |
Why?
|
Genes, APC | 1 | 2020 | 144 | 0.170 |
Why?
|
Leukocyte Count | 2 | 2021 | 1602 | 0.170 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2020 | 182 | 0.160 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 272 | 0.160 |
Why?
|
Humans | 40 | 2024 | 765968 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6499 | 0.160 |
Why?
|
Neoplasm Staging | 5 | 2022 | 11206 | 0.160 |
Why?
|
Melanoma | 1 | 2017 | 5719 | 0.150 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2020 | 220 | 0.150 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13648 | 0.150 |
Why?
|
Steroids | 1 | 2022 | 933 | 0.140 |
Why?
|
Nitriles | 1 | 2022 | 982 | 0.140 |
Why?
|
Aged | 16 | 2024 | 171117 | 0.130 |
Why?
|
Female | 21 | 2024 | 396112 | 0.130 |
Why?
|
Urologic Neoplasms | 1 | 2020 | 310 | 0.130 |
Why?
|
Middle Aged | 17 | 2024 | 223009 | 0.130 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12509 | 0.130 |
Why?
|
Bacteremia | 1 | 2022 | 989 | 0.120 |
Why?
|
Body Composition | 2 | 2021 | 2439 | 0.120 |
Why?
|
Survival Analysis | 4 | 2019 | 10070 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2022 | 1672 | 0.110 |
Why?
|
Lymphocyte Count | 3 | 2021 | 790 | 0.110 |
Why?
|
Treatment Outcome | 9 | 2020 | 65188 | 0.110 |
Why?
|
Neutrophils | 3 | 2023 | 3776 | 0.100 |
Why?
|
Adipose Tissue | 2 | 2020 | 3312 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1946 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4893 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2589 | 0.090 |
Why?
|
Risk Factors | 5 | 2021 | 74840 | 0.090 |
Why?
|
Genomics | 2 | 2024 | 5929 | 0.090 |
Why?
|
Lymphocytes | 1 | 2018 | 2599 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2022 | 2226 | 0.080 |
Why?
|
Molecular Targeted Therapy | 2 | 2018 | 2822 | 0.080 |
Why?
|
Adult | 11 | 2024 | 223044 | 0.080 |
Why?
|
Aged, 80 and over | 6 | 2024 | 59489 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2021 | 2329 | 0.070 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2019 | 330 | 0.070 |
Why?
|
Nephrectomy | 2 | 2022 | 927 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2024 | 11641 | 0.070 |
Why?
|
Body Mass Index | 2 | 2021 | 13039 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2022 | 6364 | 0.060 |
Why?
|
Risk Assessment | 2 | 2022 | 24282 | 0.050 |
Why?
|
Receptors, Interleukin-2 | 1 | 2023 | 561 | 0.050 |
Why?
|
Genes, T-Cell Receptor | 1 | 2021 | 29 | 0.050 |
Why?
|
Bilirubin | 1 | 2023 | 439 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2023 | 608 | 0.050 |
Why?
|
Young Adult | 5 | 2020 | 59889 | 0.050 |
Why?
|
Renal Replacement Therapy | 1 | 2023 | 281 | 0.050 |
Why?
|
Glasgow Outcome Scale | 1 | 2021 | 102 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7478 | 0.040 |
Why?
|
Ferritins | 1 | 2023 | 600 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13632 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2022 | 11083 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 577 | 0.040 |
Why?
|
RNA Splice Sites | 1 | 2020 | 212 | 0.040 |
Why?
|
Databases, Protein | 1 | 2020 | 391 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 598 | 0.040 |
Why?
|
Eosinophils | 1 | 2023 | 945 | 0.040 |
Why?
|
Cohort Studies | 4 | 2022 | 41649 | 0.040 |
Why?
|
Patients | 1 | 2023 | 910 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2022 | 1259 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2171 | 0.030 |
Why?
|
Platelet Count | 1 | 2018 | 782 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2020 | 1718 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2023 | 1811 | 0.030 |
Why?
|
Prospective Studies | 1 | 2019 | 54802 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2022 | 2887 | 0.030 |
Why?
|
Exons | 1 | 2020 | 2391 | 0.030 |
Why?
|
United States | 1 | 2022 | 72903 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2022 | 1424 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2020 | 1365 | 0.030 |
Why?
|
Phylogeny | 1 | 2020 | 2832 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2018 | 722 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 2023 | 5501 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2020 | 1889 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2022 | 3454 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2021 | 5881 | 0.020 |
Why?
|
Critical Illness | 1 | 2023 | 2744 | 0.020 |
Why?
|
Inflammation | 2 | 2021 | 10850 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2056 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3513 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4642 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2020 | 13400 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3559 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9338 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6255 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12795 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2020 | 4958 | 0.020 |
Why?
|
Genetic Variation | 1 | 2020 | 6610 | 0.020 |
Why?
|
Logistic Models | 1 | 2018 | 13266 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2018 | 9525 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 17075 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 13462 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 14071 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 40065 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39193 | 0.010 |
Why?
|
Transcription Factors | 1 | 2018 | 12131 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20659 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 30198 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36532 | 0.010 |
Why?
|
Concepts
(134)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_